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Abstract
Purpose: Our purpose was to report outcomes in patients with Child-Pugh B or C (CP B/C) hepatocellular carcinoma (HCC) treated
with stereotactic body radiation therapy (SBRT).
Methods and Materials: Patients with HCC suitable for SBRT were prospectively enrolled in the study from 2012 to 2018. Outcomes in
patients with CP B/C were analyzed. Cox proportional hazard models were used to compare survival outcomes between baseline CP
score and post-SBRT CP score.
Results: Twenty-three patients with CP B/C with a total of 29 HCC tumors were treated with SBRT. Eighty-seven percent of patients
were CP B8-C10. Median tumor size was 3.1 cm (range, 1-10 cm). Median dose delivered was 40 Gy in a median of 5 fractions.
Eighteen of 23 patients (78.3%) had been previously treated with transarterial chemoembolization. Median follow-up was 14.5 months.
Rates of 6- and 12-month local control were 100% and 92.3%, respectively. Six- and 12-month survival rates were 73.9% and 56.5%,
respectively. Median survival was 14.5 months overall and 9.2, 22.5, 14.5, and 14.4 months for patients with CP B7, B8, B9, and C10,
respectively. No patients exhibited symptoms of classic radiation-induced liver disease. However, 10 patients had CP score progression,
with 4 patients (17%) having a 2-point increase in CP score by 6 months (or time of censor). There were 7 liver-related deaths, and
based on independent review by a hepatologist, 1 of these deaths may have been attributable to SBRT-related liver injury. Fifteen of 23
patients were listed for liver transplant (LT) at the time of SBRT and 9 went on to receive LT with a pathologic complete response rate
of 63.6%. Median survival, excluding patients who received LT, was 7.3 months.
Conclusions: SBRT is a reasonable treatment option for carefully selected patients with CP B7-C10. In our small cohort, there was no
detectable difference between local control or overall survival and baseline CP score.
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
There is emerging evidence establishing stereotactic
body radiation therapy (SBRT) as a safe and efficacious
local treatment option for patients with localized hepato-
cellular carcinoma (HCC).1-3 Local control (LC) ranges
from 84% to 100%.4,5 However, the majority of the
published reports on SBRT for HCC have focused on
patients with well-compensated Child-Pugh (CP) A liver
function. A few reports have included patients with CP B,
and most of these patients had CP B7.3,6,7 There are also
reports that suggest increased risk of toxicity in patients
with CP B (vs A) and prescription dose reduction and
tighter liver dose constraints have been recommended.3,6-8
Treatment options for patients with CP B/C impaired
liver function are limited owing to concerns for toxicity,
and many patients are treated with best supportive care as
the risk of dying from their underlying liver disease or
treatment-related toxicity may outweigh the risk of dying
from HCC progression. The Barcelona Clinic Liver
Cancer staging system deems all patients with CP C as
stage D and recommends only best supportive care with a
life expectancy of 3 months regardless of HCC size or
extent.9 The purpose of this study was to address the
current gap in the literature regarding the tolerability and




In 2012, our institution at the UMass Memorial Med-
ical Center established a weekly multidisciplinary HCC
clinic and simultaneously launched a SBRT for HCC
program. All new and established patients with HCC were
presented at our institution’s weekly multidisciplinary
HCC conference attended by the following disciplines:
radiology, hepatology, transplant surgery, interventional
radiology, medical oncology, and radiation oncology.
Pathologic confirmation of HCC was not required as long
as radiographic and clinical criteria were met.10 All
nonmetastatic patients were evaluated regarding suit-
ability for locoregional therapies including resection,
radiofrequency ablation, microwave ablation, transarterial
chemoembolization (TACE), transarterial radio-
embolization, and SBRT. Patients with tumors amenable
to SBRT that were not eligible for other local treatment
options were referred for SBRT. Prior liver-directed
therapy was allowed. Patients listed for liver transplant
(LT) were also eligible. In 2012, our institutional review
board approved database of all HCC patients treated with
SBRT was created, and in 2014 it was converted to a
prospective database requiring informed consent for
participation from all patients.
Radiation treatment
Patients were simulated with customized vacuum
cushion and wing board for immobilization in the supine
position with arms extended overhead. A 3-dimensional
CT followed by 4-dimensional gated CT scan was ob-
tained for motion awareness and treatment planning.
Contrast enhanced diagnostic imaging was fused to CT
simulation scan for target delineation. The 4-dimensional
gated CT scan was used to define the internal target
volume and a minimum of a 3-mm margin expansion was
used for the planning target volume.
All patients were treated by volumetric modulated arc
therapy in the form of RapidArc with 6 MV or 6 MV flat-
tening filter free photon beam generated by Varian Trilogy
or STX linear accelerator equipped with high definition
multileaf collimators. Maximum allowed dose rate was set
to 1400 MU/min. Individualized optimization was per-
formed using multiple coplanar or noncoplanar, mono-
isocentric arcs. Patients were treated with free breathing.
Cone beam CT was performed before each treatment to
verify target and normal tissue localization and was
reviewed by the treating radiation oncologist. Patients were
treated with SBRT 30 to 50 Gy in 4 to 6 fractions over a 2 to
3 week period. The goal was to keep the mean liver dose
<8.8 Gy for CP B and<6 Gy for CP C. An additional liver
planning objective was to spare a minimum of 700 cm3 of
liver to <15 Gy.11 Maximum dose to 0.5 cm3 of stomach,
esophagus, and duodenum was 30 Gy and 32 Gy for large
bowel. Chest/abdominal wall V30 was limited to 30 cm3.
Follow-up
Patients were seen weekly during SBRT, 1 and 3
months post-SBRT, and then every 3 months thereafter.
Blood work was obtained at every visit post-SBRT and
imaging was obtained every 3 months. Blood work
included a complete blood count, comprehensive meta-
bolic panel, alpha fetalprotein, and international normal-
ized ratio. Imaging was either a 4 phase liver CT or
magnetic resonance imaging. All imaging was reviewed
by a body radiologist on the HCC multidisciplinary team.
Radiographic response was assessed based on modified
Response Evaluation Criteria in Solid Tumors (mRE-
CIST) for enhancing tumors, RECIST v1.1 for tumors
lacking classic enhancement pattern, alpha fetalprotein
trend, and overall impression of the radiologist.10
Treatment-related adverse events were defined by the
multidisciplinary HCC team as those judged to be due to
SBRT and not worsening of the underlying cirrhosis or
progression of disease. All patients with liver-related
mortality were independently reviewed by a single hep-
atologist to determine whether the cause of death was
most likely attributable to cancer progression, SBRT-
related complications, or the natural history of cirrhosis.
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The hepatologist took into consideration each patient’s
pretreatment liver function trajectory, including data such
as model for end-stage liver disease score trend over time,
tolerance of other therapeutic interventions in the past,
and history and frequency of liver-related de-
compensations. Importantly, the hepatologist also evalu-
ated time course between SBRT treatment, liver function
decline, and ultimately death as well as other potentially
contributing factors to the patient’s decline in liver
function.
Endpoints
Primary endpoints were survival, LC, and toxicity
within 6 months of treatment. LC was defined as complete
response, partial response, or stable disease within the
irradiated region of the liver. Local recurrence (LR) was
defined as progression of disease within the irradiated
region of the liver. Elsewhere liver recurrence (ELR) was
defined as appearance of disease beyond the region of
irradiated liver. Secondary endpoint was cause of death.
Statistical analysis
Overall survival (OS) was calculated from completion
of SBRT. OS and LC were evaluated using the Kaplan-
Meier method. Survival is reported including and
excluding LT patients. Cox proportional hazards models
were used to compare survival outcomes between base-
line CP score and post-SBRT CP score. All analyses were
performed using Stata version 11.1 software (College
Station, TX).
Results
Sixty-five consecutive patients with HCC treated with
SBRT at our institution have been enrolled into the
database. Twenty-three CP B/C patients with 29 tumors
were identified. Baseline patient and tumor characteristics
are shown in Table 1. Three, 6, 9, and 5 had CP B7, B8,
B9, and C10 scores, respectively. Most patients had un-
derlying liver disease related to alcohol consumption
(35%), hepatitis C (13%), or both (35%). Median age at
time of SBRT was 62 years (range, 41-82 years), and 83%
were men. Median size of lesion treated was 3.1 cm
(range, 1-10 cm). Eighteen patients had been previously
treated with TACE; 10 patients were referred for salvage
SBRT after LR post-TACE and 8 were referred for
combined modality treatment. Median time interval be-
tween TACE and SBRT was 178 days and 46 days for
salvage and combined modality treatment, respectively.
Only 1 patient had portal vein tumor thrombus.
Treatment details are shown in Table 2. Median dose
delivered was 40 Gy in a median of 5 fractions. Mean
uninvolved liver dose was constrained to a median dose
of 7 Gy (3.1-10.4 Gy) overall and 4.8 Gy for patients with
CP C. Median treatment interval was 14 days.
Treatment results are shown in Table 3. Median follow-
up (FU) was 14.5 months (1-67.1) with a median FU for all
living patients of 34.3 months (24.2-67.1). LC was 100% at
6 months and 92.3% at 1 year. The 1 LR was a marginal
failure (new focus of enhancement just inferior to the treated
area) in a patient with B9 with biopsy-proven HCC with
only noncontrast imaging before SBRT due to diminished
kidney function. In retrospect, the lack of contrast-enhanced
imaging limited the ability to clearly define the SBRT target
volume. She received 44 Gy in 4 fractions with a coplanar
volumetric modulated arc therapy plan. Ten months after
SBRT, her kidney and liver function had significantly
improved (glomerular filtration rate improved from 36-55
and CP score improved from B9 to B7), and she was able to
undergo a 4-phase contrast enhanced liver CT. She was
successfully salvaged with TACE and is still alive with no
evidence of disease at the time of this study. Six patients had
LC while developing ELR.
Median OS was 14.5 months with 6- and 12-month
survival rates of 73.9% and 56.5%, respectively. When
excluding patients who received liver transplant from the
survival analysis, median OS was 7.3 months (Fig 1a).
Median OS for CP B7, B8, B9, and C10 groups were 9.2,
22.5, 14.5, and 14.4 months. One-year OS for the patients
with CP C10 was 60%. There was no statistical difference
in all-cause mortality or liver-related mortality based on
baseline CP score 7 to 8 versus 9 to 10, P Z .88 and P Z
.22, respectively (Fig 1b).
Of the 15 patients listed for transplant, 9 went on to
receive LT with a median time interval between SBRT and
LT of 7 months (9-680 days). The pathologic complete
response rate is 63.6%. Seven of the 9 LT patients are alive
and without HCC recurrence at the time of this analysis
with amedian FUof 34.3months (9.1-67.1). The 2-year OS
for LT patients is 88.9%. One LT patient died of post-
operative complications that were not related to SBRT.
Another LT patient passed away at home from unknown
causes. Five patients died while awaiting LT and 1 patient
was delisted owing to a diagnosis of oropharyngeal cancer,
resulting in a dropout rate of 33.3%. No patients were
delisted owing to HCC disease progression.
Toxicity
The most common acute toxicity was grade 1 to 2
fatigue in 43% and nausea in 30%. There was no grade 3
or higher toxicity seen during treatment. In the subacute
period, defined as 1 to 6 months posttreatment, no patients
developed classic radiation-induced liver disease. Two
patients developed an increase in baseline ascites
requiring increased frequency of paracenteses, and 1 pa-
tient developed bland right portal vein thrombus 1 month
after completing SBRT. The area of the portal vein that
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developed thrombus received a maximum dose of 12 Gy.
His CP score increased from B7 to B9 at the time of
developing the PVT, and 6 months after SBRT he
received orthotopic liver transplant (OLT) with a patho-
logic complete response in the treated tumor.
The effect of SBRT on liver function is shown in
Table 4 with regard to effect on CP score and liver en-
zymes. The following changes in CP score at 6 months
after SBRT (or time of censor) were noted: 5 improved, 7
remained stable, and 10 progressed with a median CP
score change of 0. Of those who had CP improvement, all
5 had improvement by 1 point. Of those with CP score
progression, 6 progressed by 1 point, 3 progressed by 2
points, and 1 progressed by 3 points. Of the 10 patients
who had CP progression, 8 have died and 5 of the deaths
were liver related. CP progression post-SBRT was
significantly correlated with decreased OS (P Z .04;
hazard ratio [HR], 3.29; 95% confidence interval [CI],
1.06-10.18) and a trend toward increased liver-related
mortality (P Z .06; HR 4.78; 95% CI, 92-24.95) (Fig
1c). Median mean liver dose (MLD) was not statisti-
cally different between patients who had CP progression
versus CP stability/improvement (6.5 Gy compared with
6.8 respectively; P Z .76). The median MLD was also
not statistically different between patients who experi-
enced a liver-related mortality and those who did not (6.1
Gy and 6.9 Gy; P Z .45).
Of the Common Terminology Criteria for Adverse
Events v5.0 liver enzyme parameters, 1 patient had grade
2 increase in aspartate aminotransferase and 1 patient had
grade 3 increase in alkaline phosphatase within 6 months
of radiation therapy. All other patients saw grade 0 to 1
Common Terminology Criteria for Adverse Events
parameter changes in aspartate aminotransferase, alkaline
phosphatase, and alanine aminotransferase levels.
Seven patients died of liver-related issues. Based on
independent review by a hepatologist, it was determined
that of the 7 deaths, 1 may have been partially attributable
to SBRT-related liver injury. The other 6 deaths were
either related to HCC progression (ELR, portal vein tumor
thrombus, or distant metastasis) or the natural progression
of cirrhosis (Table 5). Six of the 7 liver-related mortalities
had more advanced cirrhosis with a baseline CP score of
B9 or C10, whereas 1 had a baseline CP of B7 but pro-
gressed rapidly to C10 within 1 month of SBRT. There
was no statistically significant difference in risk of
developing a liver-related mortality and baseline CP score
when comparing CP 9-10 patients with CP 7-8 patients
(HR, 3.7; P Z .225; 95% CI, 446-30.85). For this subset
Table 1 Baseline patient and tumor characteristics: Patient information including starting CP score, age, tumor size, etiology of
liver disease, and therapies before SBRT
Baseline patient and tumor characteristics All patients CP 7 CP 8 CP 9 CP 10
No patients 23 3 6 9 5
Median age (range) 62 (41-82) 62 61.5 56 65
Median tumor size (range) 3.1 cm (1-10) 4 cm 2.7 cm 2.6 cm 3.2 cm
Etiology of liver disease
EtOH 8 1 1 3 3
HCV 3 1 1 1 0
HBV 1 0 0 1 0
NASH 2 1 1 0 0
PBC 1 0 1 0 0
EtOH þ HCV 8 0 2 4 2
All patients Median interval
Total no. previous TACE 18 3 5 5 5 75.5 days
Salvage 10 1 3 4 2 178 days
CMT 8 2 2 1 3 46 days
Abbreviations: CMT Z combined modality treatment; CP Z Child-Pugh; EtOH Z ethanol; HBV Z hepatitis B; HCV Z hepatitis C; NASH Z
nonalcoholic steatohepatitis; PBC Z primary biliary cirrhosis; SBRT Z stereotactic body radiation therapy; TACE Z transarterial
chemoembolization.
Table 2 Treatment information: SBRT details stratified by
starting CP score, including tumor size, prescribed dose,
MLD, and treatment interval between first and last doses
Treatment
information
All patients CP 7 CP 8 CP 9 CP 10










40 Gy 40 Gy 35 Gy 40 Gy
MLD (range) 7 Gy
(3.1-10.4)




14 d 15 d 13.5 d 14 d 12 d
Abbreviations: CP Z Child-Pugh; MLD Z mean liver dose; SBRT
Z stereotactic body radiation therapy.
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of 7 patients who died of liver-related issues, the median
survival was 7.3 months after SBRT and the 6- and 12-
month OS rates were 57.1% and 14.3%, respectively.
Discussion
CP class was initially designed to predict survival after
porto-systemic shunting in patients with cirrhosis.12 It
was later found to be predictive of survival after surgery
and was then extrapolated to predict outcomes after other
liver-directed therapies.13-15 The CP scoring system is
fraught with subjectivity (degree of encephalopathy or
ascites), and small variations in laboratory values can
result in score or even class changes. Despite these lim-
itations, it remains the most-studied measure of liver
function in the SBRT literature. Current guidelines still
use CP score to determine eligibility for SBRT, pre-
scription dose, fractionation, and mean liver dose con-
straints. Although baseline CP score did not correlate with
risk of all-cause or liver-related mortality, an increase in
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 # At Risk
CP Stable/Imp.
CP Progression
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A B
C
Figure 1 Survival curves: (a) Kaplan-Meier survival curves of all patients, orthotopic liver transplant (OLT) patients excluded, and
only OLT patients. Median overall survival (OS) Z 14.5 months. Median OS excluding OLT Z 7.3 months. (b) Patients with starting
Child-Pugh (CP) score of 7/8 and CP 9/10. There was no significant difference of survival rates between CP 7/8 vs 9/10. (c) Patients
with stable or improved CP score after stereotactic body radiation therapy (SBRT) and patients with CP score progression. Patients with
CP progression had significantly decreased OS rate (P Z .039).
Table 3 Treatment results: Results after SBRT stratified by
starting CP score, including 1-year survival rate, median






CP 7 CP 8 CP 9 CP 10
1-year
survival
52.10% 33% 66% 44.40% 60%
OS 14.5 mo
(1-67.1)
9.2 mo 22.5 mo 14.5 mo 14.4 mo
OLT 9 2 3 2 2
CR 13 1 4 4 4
PR 6 1 1 3 1
SD 1 0 1 0 0
LR 1 0 0 1 0
N/A 2 1 0 1 0
Total 23 3 6 9 5
Abbreviations: CP Z Child-Pugh; CR Z complete response; LR Z
local recurrence; OLT Z orthotopic liver transplant; OS Z overall
survival; PR Z partial response; SBRT Z stereotactic body radia-
tion therapy; SD Z stable disease.
N/A e data unavailable.
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cause mortality and a trend toward liver-related mortality.
However, there was no clear correlation between baseline
CP score and risk of CP progression after SBRT; 37.5%
of patients with a starting CP of 7 or 8 saw progression of
their score, while 50% of those with a starting CP of 9 or
10 saw progression (P Z .675). Thus, it appears that
among patients with CP B7-C10, change in CP after
SBRT is prognostic while baseline CP by itself is not;
however, a strong statistical conclusion here is limited by
the small sample size of this study. It is important to note
that while a statistically significant correlation to starting
CP score was not found, the majority of patients who
suffered from a liver-related death did have a starting CP
score of B9 or C10. Overall, the utility of baseline CP
score to determine eligibility for SBRT should be re-
evaluated and patients with more advanced CP scores
should not automatically be deemed ineligible.
At our institution’s HCC multidisciplinary conference,
we use a more comprehensive approach to measure liver
function that includes CP score as well as performance
status, comorbidities, model for end-stage liver disease
score, other decompensations like thrombocytopenia and
history of upper gastrointestinal bleed, and tolerance to
previous liver-directed therapies. Feedback from a hep-
atologist who knows a patient’s liver history intimately
and from interventional radiologists regarding how a pa-
tient has tolerated previous treatments factors critically
into selecting which patients with CP B/C disease would
benefit from treatment with SBRT.
Culleton et al6 represents another institution with a
comprehensive multidisciplinary team approach to the
management of HCC, and their outcomes of SBRT in
patients with CP B/C were published in 2014. Compared
with our cohort, their series had more advanced HCC
(76% had tumor thrombus, 24% had extrahepatic HCC,
the median number of tumors treated was 2, and the
median sum of the largest diameter was 8.6 cm) but less


















Y 1 Progression of
encephalopathy,
edema
435 d Progression of
HCC elsewhere
in the liver and
progression of cirrhosis
B9 Encephalopathy Y 1 Encephalopathy
stable
282 d Progression of HCC
elsewhere in the liver
B9 ESRD, ascites Y 0 SBP/sepsis 216 d Progression of cirrhosis
C10 GI bleed, ascites,
encephalopathy
Y 2 Volume overload,
progression of
encephalopathy
239 d Progression of
cirrhosis and SBRT-
related liver injury
(MLD Z 5.6 Gy)




C10 None Y 1 Cholecystitis 163 d Progression of HCC
elsewhere (peritoneal
carcinomatosis)
B9 Refractory ascites Y 2 Peritonitis 26 d Progression of cirrhosis
Abbreviations: CP Z Child-Pugh; ESRD Z end-stage renal disease; GI Z gastrointestinal; HCC Z hepatocellular carcinoma; IVC Z inferior vena
cava; LC Z local control; MLD Z mean liver dose; PVTT Z portal vein tumor thrombosis; SBP Z spontaneous bacterial peritonitis; SBRT Z
stereotactic body radiation therapy.
Table 4 CP score and adverse events: Change in CP score




All patients CP 7 CP 8 CP 9 CP 10
No patients 23 3 6 9 5
CP progression 10 (43%) 2 1 3 4
CP stability 7 (30 %) 1 3 3 0
CP improvement 5 (22 %) 0 1 3 1
Gr2 þ adverse
events
6 2 1 2 1
N/V 3 0 0 2 1
Encephalopathy 1 0 0 1 0
Ascites 2 0 1 1 0
Abbreviations: CP Z Child-Pugh; N/V Z nausea or vomiting.
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advanced cirrhosis (69% CP B7), and they excluded pa-
tients with OLT from their analysis. They also had a
lower prescription dose of 30 Gy in 6 fractions. Despite
these differences in patient population, tumor character-
istics, and treatment parameters, our median survivals
were similar when we excluded our patients with OLT
(7.3 vs 7.9 months). Given the expected natural history of
progression in patients with HCC and severe baseline
liver disease, it is important to evaluate the cost-benefit of
treating these patients with the goal of LC. Although HCC
does seem to respond quite well to radiation therapy, it is
reasonable to question whether or not LC truly benefits
these patients because they generally have poor overall
survival rates (unless they receive transplant).
The effort by Chapman et al16 to define clinically
relevant endpoints in liver toxicity after SBRT was
inspirational to our study. Although we did not identify
any correlation between starting CP score and most lab-
oratory value-based posttreatment hepatotoxicity metrics
proposed by Chapman et al, the posttreatment CP pro-
gression parameters did correlate with all-cause mortality
and trended toward correlation with liver-related mortal-
ity. Further study into progression of CP and its correla-
tion with negative outcomes is warranted.16,17 We made
similar efforts as Chapman and colleagues to define
causes of liver-related mortality. We agree that we need to
continue to move toward a consensus on how to report
liver toxicity after SBRT in patients with cirrhosis.
Toxicity rates depend on how one defines toxicity,16,18
and in this cohort of patients with decompensated livers,
it’s a challenge to distinguish treatment-related toxicity
from the natural progression of cirrhosis and disease
progression.
Owing to the paucity of liver SBRT outcome data in
CP B/C patients and aforementioned challenges in
defining SBRT-related liver toxicity, the appropriate
dose-volume parameters for cirrhotic livers are not well
understood. Many dose-volume parameters have been
studied including MLD V1, V2.5, V5, V7.5, V10, V12.5,
V15, dose to 1/3 of the liver, volume of liver spared to
<15 Gy, and volume of uninvolved liver. MLD has been
well studied in CP A patients with guidelines recom-
mending MLD of 13 to 18 Gy in 3 to 6 fractions, but there
are very limited data on appropriate MLD objectives for
patients with CP B8 or higher.11,19 A conservative and
unsubstantiated MLD < 6 Gy in 4 to 6 fractions has been
recommended for patients with more advanced cirrhosis
but is frequently not feasible without significantly
compromising prescription dose. Thus, in our study we
allowed a more liberal CP-based adaptive approach to
MLD such that the lower the CP score the higher the
allowed MLD, ranging from 6 to 8.8 Gy. We extrapolated
the MLD threshold of 8.8 Gy from Lasley et al,20 who
reported the mean MLD was 8.8 Gy among CP B patients
who did not develop liver toxicity after SBRT. However,
the majority of patients in their cohort were CP B7, with
only 4 patients with CP  B8. Our MLD was 8.8, 8, 5.4,
and 4.8 Gy for CP B7, B8, B9, and C10 patients,
respectively, and there was no correlation between MLD
and CP progression, all-cause mortality, or liver-related
mortality. Thus, it appears that using a CP-based adap-
tive approach to MLD with a constraint of ~8 Gy for CP
B7-8 and ~5 Gy for CP B9-C10 is reasonable.
The small number of subjects in our study limits the
statistical power to detect differences, and thus our out-
comes need to be validated in a larger study with subse-
quent improvement in definition of SBRT-related liver
toxicity and dose-volume parameters to limit liver
toxicity.
Conclusion
Results from our study suggest that SBRT is a
potentially safe and efficacious local modality for care-
fully selected patients with CP B7-C10 with HCC with
excellent LC. Distinguishing late SBRT-related liver
toxicity from natural progression of cirrhosis and pro-
gressive HCC is a challenge, but from our analysis, it
does not appear that baseline CP score correlated with
liver-related mortality or OS.
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